|
1
|
Yamaguchi Y, Suzuki T, Arita S, Iwashita
C, Sakamoto K, Hatakeyama E, Shimmura H, Tanabe K, Ichinose M,
Suzuki N and Yamada K: Possible involvement of urokinase-type
plasminogen activator release from human peripheral blood
lymphocytes in the pathophysiology of chronic allograft
nephropathy. Transplant Proc. 37:4276–4281. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang HY, Yang LZ, Cui MJ, Gu CM, Zhao Y,
Chen Y, Zhao D, Li TS and Chi B: Hepatocyte growth factor-induced
amelioration in chronic renal failure is associated with reduced
expression of α-smooth muscle actin. Ren Fail. 34:862–870. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Grupp C, Troche I, Klass C, Köhler M and
Müller GA: A novel model to study renal myofibroblast formation in
vitro. Kidney Int. 59:543–553. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ruiz-Ortega M, Ruperez M, Lorenzo O,
Esteban V, Blanco J, Mezzano S and Egido J: Angiotensin II
regulates the synthesis of proinflammatory cytokines and chemokines
in the kidney. Kidney Int Suppl. 82:S12–S22. 2002. View Article : Google Scholar
|
|
5
|
Okada H, Inoue T, Suzuki H, Strutz F and
Neilson EG: Epithelial-mesenchymal transformation of renal tubular
epithelial cells in vitro and in vivo. Nephrol Dial Transplant.
15:(Suppl 6). S44–S46. 2000. View Article : Google Scholar
|
|
6
|
Badid C, Mounier N, Costa AM and
Desmoulière A: Role of myofibroblasts during normal tissue repair
and excessive scarring: Interest of their assesment in
nephropathies. Histol Histopathol. 15:269–280. 2000.PubMed/NCBI
|
|
7
|
Jiang T, Zhou QS, Pi L and Huang B: Role
of angiotensin II and JAK2 signal pathway in transdifferentiation
of renal tubular cells in mice after acute ischemic followed by
reperfusion. Zhonghua Bing Li Xue Za Zhi. 38:466–471. 2009.(In
Chinese). PubMed/NCBI
|
|
8
|
Funakoshi H and Nakamura T: Hepatocyte
growth factor: From diagnosis to clinical applications. Clin Chim
Acta. 327:1–23. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Forte G, Minieri M, Cossa P, Antenucci D,
Sala M, Gnocchi V, Fiaccavento R, Carotenuto F, De Vito P, Baldini
PM, et al: Hepatocyte growth factor effects on mesenchymal stem
cells: Proliferation, migration, and differentiation. Stem Cells.
24:23–33. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dai C and Liu Y: Hepatocyte growth factor
antagonizes the profibrotic action of TGF-beta1 in mesangial cells
by stabilizing Smad transcriptional corepressor TGIF. J Am Soc
Nephrol. 15:1402–1412. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang J, Dai C and Liu Y: Hepatocyte growth
factor suppresses renal interstitial myofibroblast activation and
intercepts Smad signal transduction. Am J Pathol. 163:621–632.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li Y, Yang J, Dai C, Wu C and Liu Y: Role
for integrin-linked kinase in mediating tubular epithelial to
mesenchymal transition and renal interstitial fibrogenesis. J Clin
Invest. 112:503–516. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shimamura M, Sato N, Yoshimura S, Kaneda Y
and Morishita R: HVJ-based non-viral gene transfer method:
Successful gene therapy using HGF and VEGF genes in experimental
ischemia. Front Biosci. 11:753–759. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang W, Li C, Summer SN, Falk S, Wang W,
Ljubanovic D and Schrier RW: Role of AQP1 in endotoxemia-induced
acute kidney injury. Am J Physiol Renal Physiol. 294:F1473–F1480.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Reeves WB and Andreoli TE: Transforming
growth factor beta contributes to progressive diabetic nephropathy.
Proc Natl Acad Sci USA. 97:7667–7669. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang HY, Wang YJ, Cui MJ, Gu CM, Yang LZ,
Zhao Y, Chen Y, Zhao D, Li TS and Chi BR: Hepatocyte growth
factor-induced amelioration in renal interstitial fibrosis is
associated with reduced expression of alpha-smooth muscle actin and
transforming growth factor-beta1. Indian J Biochem Biophys.
48:308–315. 2011.PubMed/NCBI
|
|
17
|
Yan Z, Yao F and Shi YH: Effects of
irbesartan on expression of glycogen synthase kinase-3β in tubular
epithelial-mesenchymal transition induced by high glucose. Chinese
Pharmacological Bulletin. 25:225–229. 2009.
|
|
18
|
Chen J, Chen JK and Harris RC: Angiotensin
II induces epithelial-to-mesenchymal transition in renal epithelial
cells through reactive oxygen species/Src/caveolin-mediated
activation of an epidermal growth factor receptor-extracellular
signal-regulated kinase signaling pathway. Mol Cell Biol.
32:981–991. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ihle BU, Whitworth JA, Shahinfar S, Cnaan
A, Kincaid-Smith PS and Becker GJ: Angiotensin-converting enzyme
inhibition in nondiabetic progressive renal insufficiency: A
controlled double-blind trial. Am J Kidney Dis. 27:489–495. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hou FF, Zhang X, Zhang GH, Xie D, Chen PY,
Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR and Geng RW: Efficacy
and safety of benazepril for advanced chronic renal insufficiency.
N Engl J Med. 354:131–140. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li Y, Fan Q and Wang L: Significance of
JAK2/STAT3 in angiotensin II up-regulation of TGF-β1, CTGF and FN
mRNA expression on mesangial cells under hyperglucose. J Nephrol
Dialy Transplant. 18:44–48. 2009.
|
|
22
|
Kim YS, Xu ZG, Reddy MA, Li SL, Lanting L,
Sharma K, Adler SG and Natarajan R: Novel interactions between
TGF-{beta}1 actions and the 12/15-lipoxygenase pathway in mesangial
cells. J Am Soc Nephrol. 16:352–362. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ionescu E, Sauter JF and Jeanrenaud B:
Abnormal oral glucose tolerance in genetically obese (fa/fa) rats.
Am J Physiol. 248:E500–E506. 1985.PubMed/NCBI
|
|
24
|
Liu Y, Rajur K, Tolbert E and Dworkin LD:
Endogenous hepatocyte growth factor ameliorates chronic renal
injury by activating matrix degradation pathways. Kidney Int.
58:2028–2043. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mizuno S, Kurosawa T, Matsumoto K,
Mizuno-Horikawa Y, Okamoto M and Nakamura T: Hepatocyte growth
factor prevents renal fibrosis and dysfunction in a mouse model of
chronic renal disease. J Clin Invest. 101:1827–1834. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Azuma H, Takahara S, Matsumoto K, Ichimaru
N, Wang JD, Moriyama T, Waaga AM, Kitamura M, Otsuki Y and Okuyama
A: Hepatocyte growth factor prevents the development of chronic
allograft nephropathy in rats. J Am Soc Nephrol. 12:1280–1292.
2001.PubMed/NCBI
|
|
27
|
Zhang TXL: Hepatocyte growth factor and
its effect on the kidney damage. Chemistry of Life. 25:399–401.
2005.
|
|
28
|
Yamasaki N, Nagano T, Mori-Kudo I,
Tsuchida A, Kawamura T, Seki H, Taiji M and Noguchi H: Hepatocyte
growth factor protects functional and histological disorders of
HgCl(2)-induced acute renal failure mice. Nephron. 90:195–205.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cruzado JM, Lloberas N, Torras J, Riera M,
Fillat C, Herrero-Fresneda I, Aran JM, Alperovich G, Vidal A and
Grinyó JM: Regression of advanced diabetic nephropathy by
hepatocyte growth factor gene therapy in rats. Diabetes.
53:1119–1127. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang J and Liu Y: Delayed administration
of hepatocyte growth factor reduces renal fibrosis in obstructive
nephropathy. Am J Physiol Renal Physiol. 284:F349–F357. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tsuchida K, Zhu Y, Siva S, Dunn SR and
Sharma K: Role of Smad4 on TGF-beta-induced extracellular matrix
stimulation in mesangial cells. Kidney Int. 63:2000–2009. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rekola S, Bergstrand A and Bucht H:
Deterioration rate in hypertensive IgA nephropathy: Comparison of a
converting enzyme inhibitor and beta-blocking agents. Nephron.
59:57–60. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Taal MW and Brenner BM: Renoprotective
benefits of RAS inhibition: From ACEI to angiotensin II
antagonists. Kidney Int. 57:1803–1817. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nakano N, Morishita R, Moriguchi A,
Nakamura Y, Hayashi SI, Aoki M, Kida I, Matsumoto K, Nakamura T,
Higaki J and Ogihara T: Negative regulation of local hepatocyte
growth factor expression by angiotensin II and transforming growth
factor-beta in blood vessels: Potential role of HGF in
cardiovascular disease. Hypertension. 32:444–451. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lu TC, Wang ZH, Feng X, Chuang PY, Fang W,
Shen Y, Levy DE, Xiong H, Chen N and He JC: Knockdown of Stat3
activity in vivo prevents diabetic glomerulopathy. Kidney Int.
76:63–71. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pang M, Ma L, Gong R, Tolbert E, Mao H,
Ponnusamy M, Chin YE, Yan H, Dworkin LD and Zhuang S: A novel STAT3
inhibitor, S3I-201, attenuates renal interstitial fibroblast
activation and interstitial fibrosis in obstructive nephropathy.
Kidney Int. 78:257–268. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Levy O and Granot Y: Arginine-Vasopressin
activates the JAK-STAT pathway in vascular smooth muscle cells. J
Biol Chen. 281:15597–15604. 2006. View Article : Google Scholar
|
|
38
|
Banes AK, Shaw S, Jenkins J, Redd H, Amiri
F, Pollock DM and Marrero MB: Angiotensin II blockade prevents
hyperglycemia-induced activation of JAK and STAT proteins in
diabetic rat kidney glomeruli. Am J Physiol Renal Physiol.
286:F653–F657. 2004. View Article : Google Scholar : PubMed/NCBI
|
